Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Wave Life Sciences (WVE) Equity Average (2016 - 2026)

Wave Life Sciences filings provide 12 years of Equity Average readings, the most recent being $515.0 million for Q1 2026.

  • On a quarterly basis, Equity Average rose 170.14% to $515.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $515.0 million, a 170.14% increase, with the full-year FY2025 number at $363.9 million, up 192.15% from a year prior.
  • Equity Average hit $515.0 million in Q1 2026 for Wave Life Sciences, up from $321.5 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $515.0 million in Q1 2026 to a low of -$46.1 million in Q3 2023.
  • Median Equity Average over the past 5 years was $16.2 million (2022), compared with a mean of $87.8 million.
  • Biggest five-year swings in Equity Average: crashed 448.9% in 2023 and later skyrocketed 41122.78% in 2024.
  • Wave Life Sciences' Equity Average stood at -$24.8 million in 2022, then soared by 98.27% to -$428000.0 in 2023, then skyrocketed by 41122.78% to $175.6 million in 2024, then surged by 83.08% to $321.5 million in 2025, then surged by 60.22% to $515.0 million in 2026.
  • The last three reported values for Equity Average were $515.0 million (Q1 2026), $321.5 million (Q4 2025), and $131.9 million (Q3 2025) per Business Quant data.